The current diagnostic techniques for prostate cancer (including serum PSA level measurement) lack sufficient specificity and sensitivity to determine the aggressiveness of the disease and to identify appropriate treatment. Thus, additional biomarkers are needed that can facilitate early diagnosis, determine the patient's prognosis and predict responses to a given therapeutic intervention. In this Perspectives article, the authors argue that patented biomarkers are the closest to market and can be used to assess progress in this field.
- Lisa Murphy
- R. William Watson
